Bloom Diagnostics

Operating from Zurich, Switzerland, with offices in Vienna, Bloom Diagnostics is a medtech company focused on making health analysis more accessible. Founded in 2018 by Dr. Angelica Kohlmann and Thomas Kupper, the company aims to bridge the gap between technology and personal healthcare. Dr. Kohlmann, with a background in cancer research, pharmaceuticals, and venture capital, identified a need to bring healthcare closer to individuals through technology. This led to the creation of Bloom Diagnostics, where her medical and investment experience converges with Kupper's role as Chief Product Officer.

The company's core offering is the Bloom System, a platform that combines a physical device (the Bloom Lab), disposable test strips (Bloom Test), and a mobile application (Bloom App) to provide rapid blood marker analysis. This integrated system allows individuals and professionals at partner locations like pharmacies to conduct tests using a few drops of blood. The Bloom Lab analyzes the test strip, detecting specific biomarkers based on lateral flow immunoassay technology, and securely transmits encrypted results to the user's app in minutes. The app then provides a personalized report, combining the test results with self-reported symptoms and lifestyle data to offer actionable health insights. The entire process emphasizes data privacy through full encryption, ensuring only the user can access their results.

Bloom Diagnostics targets both individual consumers interested in proactively managing their health and B2B partners, such as pharmacies, that wish to offer on-site diagnostic services. Its product line includes tests for various health indicators, such as iron levels (Ferritin), thyroid function (TSH), inflammation (CRP), ovarian reserve (AMH), and kidney health. The business model involves the sale of the reusable Bloom Lab device and the consumable, single-use Bloom Test strips for different biomarkers. The company has secured approximately $22 million in funding over several rounds, including a Series B round of about $11.7 million in 2020, to fuel research and development and international expansion across Europe and the US.

Keywords: at-home testing, diagnostics, medtech, blood analysis, personalized health, digital health, immunoassay, point-of-care, health monitoring, biomarker tracking